Mechanism of action<unk>  binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα), making it a receptor antagonist. Through blockade of IL-4Rα,<unk>  modulates signaling of both the interleukin 4 and interleukin 13 pathways. Pharmacokinetics<unk>  shows a non-linear rate in regard to the target.<unk>  is also reported to have a bioavailability of 64%, with the average concentration occurring one week after injection.
Dupilumab
Olaratumab
Emapalumab
Ustekinumab
Evolocumab
Burosumab
Sarilumab
Evinacumab